PHAR

SEC filing PHAR Discloses Internal Control Weaknesses, No Auditor Disagreements

5d ago

News Pharming GAAP EPS of $0.00 in-line, revenue of $72.4M misses by $19.67M

26d ago

SEC filing PHAR Reports $1.2B Revenue, $0.05 EPS, +18% YoY Growth, Launches New Product Line

47d ago

SEC filing PHAR Reports $1.2B Revenue, $0.05 EPS, +15% YoY Growth, Announces $300M R&D Expansion

70d ago

News Pharming outlines $405M–$425M 2026 revenue target as Joenja and RUCONEST drive growth

81d ago

News Pharming beats top-line estimates; introduces FY26 outlook

82d ago

Scanner Unusual volume (2.9x average)

119d ago

SEC filing 8-K Filing

119d ago